Hair Thinning Mounjaro - Causes & Solutions from £124.99

Our Pricing

Understanding Hair Thinning on Mounjaro: Causes, Prevalence & Management

Published: 10 September 2026

Hair thinning mounjaro is a concern raised by some patients using tirzepatide for weight loss, though it remains a relatively uncommon side effect not listed in primary clinical trial data. While rapid weight reduction from any cause can trigger telogen effluvium—a temporary form of hair shedding—understanding the mechanism, timeline, and evidence-based management strategies can help patients navigate this potential adverse effect with confidence.

What Causes Hair Thinning on Mounjaro Treatment?

Hair thinning mounjaro experiences are most commonly attributed to telogen effluvium, a stress-related hair shedding condition triggered by rapid physiological changes rather than the medication itself [1]. When patients lose significant weight quickly—often 10-15% of body weight within the first six months of tirzepatide therapy—the body interprets this as a metabolic stressor, pushing hair follicles prematurely into the resting (telogen) phase.

Nutritional deficiencies may compound this effect, particularly when caloric restriction is severe. Rapid weight loss can deplete protein, iron, zinc, and biotin stores—all essential micronutrients for healthy hair growth [2]. The SURPASS clinical trial programme did not list alopecia as a statistically significant adverse event, suggesting hair thinning occurs in a minority of patients and is likely multifactorial rather than a direct pharmacological effect of tirzepatide.

How Common Is Hair Thinning with Mounjaro in UK Patients?

Clinical trial data from the SURPASS studies, which enrolled over 6,000 participants, did not identify hair thinning mounjaro as a common adverse reaction [3]. Post-marketing surveillance and patient forums suggest hair shedding affects an estimated 5-10% of users, typically those experiencing the most dramatic weight reduction. This incidence aligns closely with telogen effluvium rates observed in bariatric surgery patients and those following very low-calorie diets.

UK prescribers report that hair thinning complaints tend to emerge 3-6 months after initiating Mounjaro, coinciding with peak weight loss velocity. The condition is generally self-limiting, with hair regrowth resuming once weight stabilises and nutritional status normalises. Importantly, permanent hair loss has not been documented in association with tirzepatide therapy.

Risk Factors for Hair Thinning on Mounjaro

Patients most susceptible to hair thinning mounjaro include those with pre-existing nutritional deficiencies, rapid weight loss exceeding 1.5 kg per week, inadequate protein intake below 60g daily, and concurrent metabolic stressors such as thyroid dysfunction or iron deficiency anaemia [4]. Women, particularly those with a history of telogen effluvium during pregnancy or dieting, may face elevated risk.

Managing Hair Thinning While on Mounjaro Therapy

Evidence-based strategies to minimise hair thinning mounjaro involve optimising nutritional intake, moderating the pace of weight loss, and ensuring adequate micronutrient status. Patients should aim for at least 1.2g protein per kilogram of ideal body weight daily, prioritising lean meats, fish, eggs, and legumes to support keratin synthesis [5].

Supplementation with a comprehensive multivitamin containing biotin (30mcg), iron (14-18mg for premenopausal women), zinc (10mg), and vitamin D (10mcg) can address common deficiencies. However, biotin megadoses above 300mcg lack robust evidence and may interfere with laboratory thyroid function tests. UK pharmacists recommend serum ferritin and thyroid function screening before initiating high-dose supplementation.

When to Seek Medical Review

Patients experiencing hair thinning mounjaro should consult their prescriber if shedding persists beyond six months, involves patchy bald spots rather than diffuse thinning, or is accompanied by scalp inflammation or scarring. These features may indicate an alternative diagnosis requiring dermatological assessment rather than simple telogen effluvium.

Hair Thinning Mounjaro vs Other Weight Loss Treatments

Hair thinning mounjaro patterns mirror those observed with other GLP-1 receptor agonists, including semaglutide (Wegovy) and liraglutide (Saxenda), as well as non-pharmacological weight loss interventions [6]. The common denominator is rapid caloric deficit rather than medication class, suggesting this is a physiological response to negative energy balance.

Orlistat, which works via fat malabsorption rather than appetite suppression, carries a theoretical risk of fat-soluble vitamin deficiency (A, D, E, K) but has not been strongly associated with telogen effluvium in clinical practice. Patients prioritising hair health may benefit from slower, more gradual weight reduction protocols, though this must be balanced against cardiometabolic benefits of timely weight loss.

Timeline and Prognosis for Hair Thinning on Mounjaro

The typical timeline for hair thinning mounjaro follows a predictable pattern: shedding begins 2-4 months after treatment initiation, peaks at 4-6 months, then gradually resolves over the subsequent 6-12 months as the hair growth cycle normalises [7]. This delay reflects the hair follicle's natural growth cycle—telogen hairs shed 3-4 months after the triggering stressor.

Regrowth is generally complete within 12-18 months of weight stabilisation, with hair density returning to baseline in the vast majority of cases. Patients should be reassured that telogen effluvium is a reversible condition, and continued Mounjaro therapy does not prevent hair recovery provided nutritional status is optimised.

Supporting Hair Regrowth During Treatment

Topical minoxidil 5% solution applied once daily may accelerate hair thinning mounjaro recovery by prolonging the anagen (growth) phase, though evidence specifically in GLP-1 users is limited [8]. Gentle hair care practices—avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments—reduce mechanical stress on weakened follicles during the recovery period.

Accessing Mounjaro Through Cured Pharmacy UK

Cured Pharmacy supplies genuine Mounjaro (tirzepatide) from £124.99 following online clinical assessment by UK-registered prescribers, with transparent pricing displayed before consultation. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all dispensing to ensure compliance with MHRA guidelines and patient safety standards.

Patients concerned about hair thinning mounjaro can discuss risk mitigation strategies during their consultation, including baseline nutritional screening and personalised dietary guidance. New customers receive £20 off their first order with code Weightlossnew, and all prescriptions include free discreet delivery across the UK. Treatment requires clinical suitability assessment and is subject to prescriber approval based on individual medical history and contraindications.

Jump to your dose (first-order price, 4-week pen):

Has the price of Mounjaro gone up?

Yes. From 1 September 2025, Eli Lilly raised the UK list price of Mounjaro, so pharmacies now pay more for every pen. The Pharmaceutical Journal reports that the cost to pharmacies moved from a range of £92 to £122 a pen to £133 for the 2.5mg pen and £330 for the 12.5mg and 15mg pens. For the highest dose, RTÉ reports that Lilly put the monthly price at £330, up from £122, which is a rise of about 170%.

The increase applies to private prescriptions. The Pharmaceutical Journal reports that NHS commissioning of tirzepatide is unaffected by the change in list price. Lilly confirmed the change on 15 August 2025.

Lilly sets the list price, but each pharmacy sets its own price and may receive rebates, which is why the same pen can cost different amounts.

Our current prices: on your first order with code Weightlossnew, Mounjaro is £124.99 at 2.5mg, £159 at 5mg and £267 at 15mg, with your consultation and delivery included. Prices checked 12 November 2026. See every dose.

Could it change again? Pharmacy prices can change at any time, so every price on this page carries the date it was checked, and we review the page again by 12 May 2027.

Mounjaro prices by dose and related guides

Every Mounjaro strength has its own price page, and each guide below answers one question in more detail. Prices shown are the first-order price with code Weightlossnew, checked 12 November 2026, and include your consultation and delivery.

Reviewed by

Tarun Kumar, Superintendent and Prescribing Pharmacist

GPhC registration 2233073. Pharmacy graduate of Aston University (2022) with a community pharmacy background, and co-founder of Cured Pharmacy (GPhC 9012511). Meet our clinical team · Check the GPhC register

Page last reviewed 12 November 2026. Next review: 12 May 2027.

Scientific References

1. Harrison, S., & Bergfeld, W. (2009). Diffuse hair loss: its triggers and management. Cleveland Clinic Journal of Medicine, 76(6), 361-367. [accessed 10 September 2026]
2. Guo, E. L., & Katta, R. (2017). Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatology Practical & Conceptual, 7(1), 1-10. [accessed 10 September 2026]
3. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 10 September 2026]
4. Brandt, K. G., & de Castro Antunes, M. M. (2020). Acute telogen effluvium after bariatric surgery: a systematic review. Obesity Surgery, 30(11), 4598-4604. [accessed 10 September 2026]
5. Almohanna, H. M., Ahmed, A. A., Tsatalis, J. P., & Tosti, A. (2019). The role of vitamins and minerals in hair loss: a review. Dermatology and Therapy, 9(1), 51-70. [accessed 10 September 2026]
6. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 10 September 2026]
7. Malkud, S. (2015). Telogen effluvium: a review. Journal of Clinical and Diagnostic Research, 9(9), WE01-WE03. [accessed 10 September 2026]
8. Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy, 13, 2777-2786. [accessed 10 September 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.
12. Pharmaceutical Journal. (2025). Reimbursement for NHS Mounjaro dispensing confirmed for September 2025. https://pharmaceutical-journal.com/article/news/reimbursement-for-nhs-mounjaro-dispensing-confirmed-for-september-2025 Accessed 12 November 2026.
13. Pharmaceutical Journal. (2025). UK's biggest online pharmacy freezes Mounjaro price amid reports of 'stockpiling'. https://pharmaceutical-journal.com/article/news/uks-biggest-online-pharmacy-freezes-mounjaro-price-amid-reports-of-stockpiling Accessed 12 November 2026.
14. RTÉ. (2025). Lilly to hike UK price of Mounjaro weight-loss drug by 170%. https://www.rte.ie/news/business/2025/0814/1528531-lilly-to-hike-uk-price-of-mounjaro-weight-loss-drug-by-170 Accessed 12 November 2026.
15. Eli Lilly and Company Limited. Mounjaro KwikPen solution for injection in pre-filled pen: Summary of Product Characteristics. electronic Medicines Compendium (emc). https://www.medicines.org.uk/emc/product/15484/smpc Accessed 12 November 2026.
16. National Institute for Health and Care Excellence. (2024). Tirzepatide for managing overweight and obesity [TA1026]. NICE. https://www.nice.org.uk/guidance/ta1026 Accessed 12 November 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.